[ad_1]
-The expanded Phase 2 data set continues to provide compelling reasons for moving to registered clinical projects-
-Bomedemstat has demonstrated lasting clinical improvement in ET patients who have failed at least one standard therapy (usually hydroxyurea)-
-Bomedemstat is still well tolerated in general-
Imago BioSciences, Inc. (“Imago”) (NASDAQ:International organizations), a clinical-stage biopharmaceutical company that discovered a new drug for the treatment of myeloproliferative tumors (MPN), today announced its ongoing evaluation of bomedemstat’s global phase 2 clinical research in patients with essential thrombocythemia (ET). data. Data at 63road The American Society of Hematology (ASH) Annual Meeting and Exposition will be held from December 11 to 14, 2021. Previously, the Phase 2 data set with a deadline of May 18, 2021 has been submitted at the 2021 European Society of Hematology Virtual Conference.
Highlights of the update (as of November 1, 2021):
-
Among the 29 patients who received bomedemstat for more than 6 weeks:
-
100% (29/29) of patients have platelet counts reduced to the normal range (150 – 400 x 109/L).
-
90% (26/29) of patients have platelet counts below 400 x 109/L No thromboembolic events, the main composite endpoint of this study.
-
-
Among the 17 evaluable patients at 24 weeks:
-
71% (12/17) showed a decrease in the total symptom score (TSS).
-
53% (9/17) shows that TSS has decreased by ≥50%.
-
-
Patients with all genotypes identified in the study (CALR, JAK2V617F, Triple negative) in response to bomedemstat.
“As of the latest data for this Phase 2 trial, bomedemstat is used as a 2nd The line ET population showed significant and lasting hematological control and symptom improvement while maintaining normal hemoglobin levels. I am pleased with the progress we have made in this study and would like to take this opportunity to thank all the researchers and patients who participated,” said Hugh Young Rienhoff, MD, CEO of Imago BioSciences. “Even if there are only 29 recruits in our plan Of up to 60 patients, we have started planning to register clinical trials for ET. We expect to hold the second phase closing meeting and discuss the third phase agreement in the second half of 2022. ”
Safety and tolerability
-
Bomedemstat is generally well tolerated.
-
The most common AE (>20%) is dysgeusia…
The full story can be found on Benzinga.com
[ad_2]
Source link
